USS Investment Management Ltd Purchases 9,228 Shares of Zimmer Biomet Holdings, Inc. $ZBH

USS Investment Management Ltd lifted its position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 19.5% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 56,444 shares of the medical equipment provider’s stock after purchasing an additional 9,228 shares during the period. USS Investment Management Ltd’s holdings in Zimmer Biomet were worth $5,105,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently modified their holdings of the company. DV Equities LLC bought a new position in Zimmer Biomet during the fourth quarter worth about $25,000. Monetary Solutions Ltd bought a new stake in Zimmer Biomet in the fourth quarter valued at approximately $30,000. Gen Wealth Partners Inc acquired a new stake in shares of Zimmer Biomet in the fourth quarter valued at approximately $31,000. Flagship Harbor Advisors LLC bought a new position in shares of Zimmer Biomet during the 4th quarter worth approximately $32,000. Finally, Grove Bank & Trust boosted its position in Zimmer Biomet by 431.6% during the fourth quarter. Grove Bank & Trust now owns 404 shares of the medical equipment provider’s stock worth $36,000 after purchasing an additional 328 shares during the period. 88.89% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other Zimmer Biomet news, insider Sang Yi sold 5,000 shares of the business’s stock in a transaction on Friday, May 29th. The shares were sold at an average price of $82.64, for a total transaction of $413,200.00. Following the sale, the insider owned 27,251 shares of the company’s stock, valued at approximately $2,252,022.64. The trade was a 15.50% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. 1.28% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on ZBH. Robert W. Baird set a $92.00 price objective on shares of Zimmer Biomet in a research report on Wednesday, April 29th. Wells Fargo & Company reduced their price objective on shares of Zimmer Biomet from $98.00 to $90.00 and set an “equal weight” rating on the stock in a research note on Wednesday, April 29th. Wall Street Zen upgraded shares of Zimmer Biomet from a “hold” rating to a “buy” rating in a research report on Saturday, May 9th. Truist Financial reissued a “hold” rating and issued a $92.00 price objective (down from $98.00) on shares of Zimmer Biomet in a research note on Wednesday, April 29th. Finally, Citigroup lowered their price objective on shares of Zimmer Biomet from $95.00 to $93.00 and set a “neutral” rating for the company in a research report on Thursday, May 28th. One investment analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, twelve have assigned a Hold rating and three have given a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $102.70.

Zimmer Biomet Stock Up 4.0%

Shares of NYSE ZBH opened at $87.50 on Friday. The company has a current ratio of 1.73, a quick ratio of 0.95 and a debt-to-equity ratio of 0.50. The company has a market cap of $16.93 billion, a price-to-earnings ratio of 22.73, a PEG ratio of 2.48 and a beta of 0.46. Zimmer Biomet Holdings, Inc. has a 12 month low of $79.12 and a 12 month high of $108.29. The stock has a 50-day moving average price of $86.20 and a two-hundred day moving average price of $89.83.

Zimmer Biomet (NYSE:ZBH) last posted its earnings results on Tuesday, April 28th. The medical equipment provider reported $2.09 EPS for the quarter, topping analysts’ consensus estimates of $1.86 by $0.23. The firm had revenue of $2.09 billion during the quarter, compared to analysts’ expectations of $2.07 billion. Zimmer Biomet had a net margin of 9.05% and a return on equity of 13.24%. The business’s revenue for the quarter was up 9.3% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.81 earnings per share. Zimmer Biomet has set its FY 2026 guidance at 8.400-8.550 EPS. As a group, analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.48 earnings per share for the current fiscal year.

Zimmer Biomet Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, July 31st. Investors of record on Thursday, June 25th will be paid a $0.24 dividend. The ex-dividend date of this dividend is Thursday, June 25th. This represents a $0.96 annualized dividend and a yield of 1.1%. Zimmer Biomet’s dividend payout ratio is presently 24.94%.

Zimmer Biomet Profile

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.